NCT05566028 - The Efficacy and Safety of D745 Added to D150 Plus D759 Therapy in Patients with Type 2 Diabetes | Biotech Hunter

Enrollment

172

Participants

Timeline

Start Date

October 12, 2022

Primary Completion Date

January 10, 2024

Study Completion Date

July 23, 2024

Conditions

Type 2 Diabetes

Interventions

DRUG

D745 formulation I

QD for 24 weeks or 52 weeks(if extension study) with D150 and D759

DRUG

D745 formulation II

QD for 24 weeks or 52 weeks(if extension study) with D150 and D759

DRUG

D745 Placebo

QD for 24 weeks or 52 weeks(if extension study) with D150 and D759

Trial Locations (1)

Seoul National University Hospital, Seoul